Analyst Consensus ?
ConsensusBuy14 ratings
Bullish964.3%
Neutral535.7%
Bearish00.0%
Tempus AI, Inc. · TEM · FY2025 Q4 · Calendar Q1 2026
Tempus AI: Growth, AI and MRD Execution
The call analysis supports a growth case built on diagnostics expansion and data licensing, with management pointing to AI products and MRD as additional opportunities. The thesis remains execution-dependent: reimbursement, sales-force enablement, regulatory timing and competition could limit the expected contribution.
Reported After market closeNASDAQHealthcare
$12.80B market cap
90quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$-0.04
Consensus $-0.04
EPS surprise
+8.8%
Reported versus consensus
Reported revenue
$367.2M
Consensus $362.6M
Revenue surprise
+1.3%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-7.3%
Event window
SPY move
+0.8%
Same window
Abnormal move
-8.2%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
-12.9%
Up to 20 sessions
TEMSPY benchmark
Ask FN2 about TEM FY2025 Q4
Transcript, numbers and history already loaded
Why did TEM fall 7.3% after beating EPS estimates in FY2025 Q4?What changed in TEM's guidance and outlook in FY2025 Q4?Give me the bull and bear case for TEM after FY2025 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management described 2025 revenue growth above 33%, strength in diagnostics and data licensing, and a maintained 2026 outlook. The call highlighted progress on the AI foundation model and plans to expand assay offerings; MRD adoption and reimbursement remain open execution items. Prior-quarter analysis was unavailable, so a sequential narrative comparison cannot be established.
Guidance delta
Guidance was characterized as maintained. The call analysis reports 2026 revenue guidance of $1.59 billion and an expectation of positive adjusted EBITDA; no change to guidance was identified in the supplied analysis.
Key takeaways
- The call analysis describes 2025 revenue growth above 33%, with diagnostics and data licensing both contributing.
- Data licensing was described as having 126% net revenue retention, with projected growth of about 40% year over year.
- Management highlighted AI foundation-model development and planned expansion of diagnostic assays.
- MRD is a potential growth avenue, but scaling sales and reimbursement remain important execution dependencies.
Management priorities
- Expand the AI foundation model across oncology and additional therapeutic areas.
- Advance planned assay launches and regulatory steps, including xH, xE and xF.
- Enable the MRD sales force and pursue broader adoption.
- Grow data licensing and clinical-trial-matching services.
Follow TEM with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$78.48Current
$44Low
$75.74Average
$110High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 3, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Needham | Buy | Buy | Maintain | Nov 2, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Oct 26, 2026 |
| BTIG | Buy | Buy | Maintain | Oct 26, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Oct 14, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Oct 12, 2026 |
| Guggenheim | Buy | Buy | Maintain | Oct 1, 2026 |
| Piper Sandler | Overweight | Neutral | Upgrade | Sep 1, 2026 |
| Freedom Capital Markets | Hold | Hold | Maintain | Aug 31, 2026 |
| Stifel | Hold | Hold | Maintain | Aug 3, 2026 |
| TD Cowen | Buy | Buy | Maintain | May 6, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Mar 3, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jun 25, 2025 |
| William Blair | Market Perform | Outperform | Downgrade | Feb 12, 2025 |
| Loop Capital | Buy | Buy | Maintain | Jan 14, 2025 |
Named analyst price targets
Upside is calculated against the persisted current price $78.48. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Needham | Ryan Macdonald | $89 | $78.9 | +13.4% | Nov 2, 2026 |
| H.C. Wainwright | Yi Chen | $68 | $67.62 | -13.4% | Oct 26, 2026 |
| Guggenheim | Subbu Nambi | $92 | $81.22 | +17.2% | Oct 1, 2026 |
| Goldman Sachs | Analyst unavailable | $75 | $77.84 | -4.4% | Sep 21, 2026 |
| H.C. Wainwright | Yi Chen | $66 | $58.74 | -15.9% | Sep 11, 2026 |
| UBS | Douglas Schenkel | $70 | $64.29 | -10.8% | Sep 9, 2026 |
| Redburn Partners | Jamie Clark | $67 | $64.62 | -14.6% | Sep 8, 2026 |
| Raymond James | Sarah James | $80 | $62.27 | +1.9% | Sep 2, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $80 | $62.27 | +1.9% | Sep 2, 2026 |
| Piper Sandler | Analyst unavailable | $76 | $63.05 | -3.2% | Sep 1, 2026 |
| Piper Sandler | Analyst unavailable | $56 | $46.05 | -28.6% | Aug 4, 2026 |
| BTIG | Analyst unavailable | $70 | $46.78 | -10.8% | Aug 3, 2026 |
| H.C. Wainwright | Yi Chen | $56 | $46.95 | -28.6% | Aug 3, 2026 |
| Stifel Nicolaus | Analyst unavailable | $50 | $43.87 | -36.3% | Aug 3, 2026 |
| Guggenheim | Subbu Nambi | $65 | $57.25 | -17.2% | Jul 16, 2026 |
| H.C. Wainwright | Yi Chen | $64 | $49.86 | -18.5% | May 11, 2026 |
| BTIG | Analyst unavailable | $80 | $49.86 | +1.9% | May 10, 2026 |
| H.C. Wainwright | Yi Chen | $95 | $52.03 | +21.0% | Mar 10, 2026 |
| Stifel Nicolaus | Daniel Arias | $60 | $53.83 | -23.5% | Feb 25, 2026 |
| Mizuho Securities | Bradley Bowers | $100 | $56.16 | +27.4% | Feb 19, 2026 |
| Robert W. Baird | Analyst unavailable | $59 | $51.95 | -24.8% | Feb 17, 2026 |
| Canaccord Genuity | Kyle Mikson | $80 | $64.46 | +1.9% | Dec 22, 2025 |
| Morgan Stanley | Analyst unavailable | $85 | $74.07 | +8.3% | Dec 1, 2025 |
| BTIG | Mark Massaro | $105 | $76.06 | +33.8% | Nov 25, 2025 |
| Canaccord Genuity | Kyle Mikson | $95 | $84.49 | +21.0% | Nov 5, 2025 |
| Piper Sandler | Analyst unavailable | $105 | $89.1 | +33.8% | Oct 22, 2025 |
| Canaccord Genuity | Analyst unavailable | $110 | $87.78 | +40.2% | Oct 20, 2025 |
| Guggenheim | Analyst unavailable | $95 | $78.93 | +21.0% | Sep 26, 2025 |
| H.C. Wainwright | Yi Chen | $90 | $78.34 | +14.7% | Sep 2, 2025 |
| Needham | Ryan MacDonald | $70 | $58.74 | -10.8% | Aug 8, 2025 |
| Morgan Stanley | Analyst unavailable | $60 | $48.86 | -23.5% | Mar 6, 2025 |
| Piper Sandler | Analyst unavailable | $55 | $52.73 | -29.9% | Mar 4, 2025 |
| Piper Sandler | David Westenberg | $70 | $44.94 | -10.8% | Nov 12, 2024 |
| Stifel Nicolaus | Daniel Arias | $65 | $44.94 | -17.2% | Nov 11, 2024 |
| Needham | Ryan Macdonald | $56 | $44.94 | -28.6% | Nov 5, 2024 |
| Loop Capital Markets | Mark Schappel | $57 | $50.72 | -27.4% | Oct 15, 2024 |
| Bank of America Securities | Michael Ryskin | $60 | $53.07 | -23.5% | Oct 2, 2024 |
| Piper Sandler | David Westenberg | $40 | $38.75 | -49.0% | Aug 12, 2024 |
| Needham | Ryan MacDonald | $47 | $33.74 | -40.1% | Jul 9, 2024 |
| Morgan Stanley | Tejas Savant | $44 | $33.2 | -43.9% | Jul 9, 2024 |
Track every rating change on TEM the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationTempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.…
Historical context
All TEM earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +19.5% | IDEXX raises 2026 outlook as diagnostics, placements and software support growth |
| SNY Sanofi | FY2026 Q3 · Calendar Q4 2026 | +30.8% | +2.8% | Sanofi lifts 2026 outlook as Dupixent and launches drive Q3 growth |
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
Latest beats and misses
Who reports nextBeat on EPS
- MARFY2026 Q3 · November 2, 2026+6.3% EPS+4.3% move
- NBIXFY2026 Q3 · November 2, 2026+72.3% EPS-0.5% move
- AXSMFY2026 Q3 · November 2, 2026+60.6% EPS-5.8% move
- TEMFY2026 Q3 · November 2, 2026+174.7% EPS+8.7% move
- BWXTFY2026 Q3 · November 2, 2026+6.8% EPS-0.2% move
- CUBEFY2026 Q3 · October 29, 2026+2.3% EPS+4.0% move
Missed on EPS
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- PINSFY2026 Q3 · October 29, 2026-5.4% EPS-2.8% move
Get the TEM recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T00:30:44.469845+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T00:30:44.467043+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.